BCS Financial Launches Gene Therapy Stop Loss for Employer Groups
BCS Financial Launches Gene Therapy Stop Loss for Employer Groups
The product offers self-funded employer groups the option to "carve out" the gene therapy ingredient costs in a separate stop loss policy, providing protection against the therapy costs themselves, and reducing the risk of lasering and non-renewals on their traditional stop loss policy. The product is currently available for quoting in 45 states.New solution offers additional protection from gene therapy risk for self-funded employer groups
新解決方案爲自費僱主團體提供額外的基因療法風險保護
CHICAGO, Oct. 3, 2024 /PRNewswire/ -- BCS Financial today announces a new stop loss product for small to mid-sized self-funded employer groups seeking additional protection from gene therapy costs. Known as Stop Loss GTS, the product is designed to sit alongside traditional stop loss coverage and provide additional risk protection against unknown – and unprecedented – gene therapy costs.
芝加哥，2024年10月3日 / PRNewswire / - 今天，BCS Financial宣佈推出一款新的停損產品，供尋求額外保護免受基因療法成本影響的中小型自費僱主團體使用。該產品名爲Stop Loss GTS，旨在與傳統的停損保險一起運作，併爲未知 - 以及前所未有的 - 基因療法成本提供額外的風險保護。
"Gene therapies are changing modern medicine, and they are also changing the self-funded insurance market," said Mehb Khoja, BCS Head of Large Claims Solutions. "With treatments ranging $2M to $4M, it's going to be a challenge for many self-funded employer groups to finance these costs within their traditional stop loss policies. That's why we've created Stop Loss GTS – to help fill a gap in the market and provide additional protection for employers."
"基因療法正在改變現代醫學，也正在改變自費保險市場，" BCS大額索賠解決方案主管Mehb Khoja表示。"隨着治療費用介於200萬到400萬元之間，對許多自費僱主團體來說，在傳統停損政策內籌措這些費用將是一個挑戰。這就是我們創建Stop Loss GTS的原因 - 以幫助填補市場上的空白，併爲僱主提供額外的保護。"
The product offers self-funded employer groups the option to "carve out" the gene therapy ingredient costs in a separate stop loss policy, providing protection against the therapy costs themselves, and reducing the risk of lasering and non-renewals on their traditional stop loss policy. The product is currently available for quoting in 45 states.
該產品爲自費僱主團體提供了一個選項，即將基因療法成本分拆爲單獨的停損保單，提供對療法成本本身的保護，降低傳統停損政策上的單一覈算和不續保的風險。該產品目前可在45個州報價。
Stop Loss GTS is the latest addition to BCS's suite of solutions designed to provide additional protection for this growing risk.
Stop Loss GTS是BCS旨在爲這一不斷增長的風險提供額外保護的解決方案系列的最新補充。
"Our goal is to help alleviate the unexpected burden of these expenses for self-insured employers and health plans," said Khoja.
"我們的目標是幫助減輕這些意外費用對自保僱主和健康計劃的負擔，" Khoja說。
"We've had solutions in the market since 2019 when the first gene therapies were FDA approved, and have introduced new products as additional therapies have hit the market. As the gene therapy pipeline continues to grow, BCS will continue to develop new and innovative products and solutions alongside with it."
"自2019年第一種基因療法獲得FDA批准以來，我們就在市場上提供解決方案，並在其他療法進入市場時推出新產品。隨着基因療法產品管線的持續增長，BCS將繼續開發新的創新產品和方案。"
For more information about Stop Loss GTS, or other gene therapy insurance solutions, visit bcsf.com or contact your insurance broker.
了解更多有關止損GTS或其他基因療法保險解決方案，請訪問bcsf.com或聯繫您的保險經紀人。
About BCS Financial: BCS Financial Corporation has more than 70 years of experience delivering a wide-range of insurance and financial solutions for Blue Cross and Blue Shield organizations and commercial markets nationwide. Through its subsidiaries, BCS Insurance Company and 4 Ever Life Insurance Company, BCS is licensed in all 50 states and is rated A (Excellent) by A.M. Best. BCS Financial is headquartered in Oakbrook Terrace, Ill. Learn more at bcsf.com.
關於BCS Financial：BCS金融公司擁有超過70年的經驗，爲藍十字會和商業市場提供各種保險和金融解決方案。通過其子公司BCS保險公司和4 Ever人壽保險公司，BCS在所有50個州都有執照，並獲得了A.m.最佳的「A（優秀）」評級。BCS金融總部位於伊利諾伊州奧克布魯克露臺。欲知更多信息，請訪問bcsf.com。
Media Contact:
Nathan Post
Phone: 630.472.7860.
媒體聯繫人：
納森發帖
電話：630.472.7860。
SOURCE BCS Financial
來源BCS Financial
